Forbes -
15 Jan 2013 22:53
Celgene (CELG) was upgraded by Bank of America/Merrill Lynch (BAC) to buy from neutral with a price target of $115, as the firm believes that the company can experience compound annual growth of 25% during the next five years.
Share this Article